{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'deviations/violations that occur but do not affect participant safety will be submitted with the routine DSMB meeting', 'report.', '11.1.11', 'PUBLICATION AND DATA SHARING POLICY', 'This study will be conducted in accordance with the following publication and data sharing policies and regulations:', 'National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access to the published results', 'of NIH funded research. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH', 'funds to the digital archive PubMed Central upon acceptance for publication.', 'Publication of results will be based on data from UAB and UM that has been analyzed as stipulated in the statistical', 'analysis plan. We will not present data gathered from one site before the full publication, unless formally agreed to by', 'all Investigators', 'By signing the protocol, the investigators will agree to keep all information in strict confidence and to request similar', \"confidentiality from his/her staff and the IRB. Study documents (protocols, Investigators' brochures, eCRFs and other\", 'material) will be stored appropriately to ensure their confidentiality. Individual patient data obtained during this study', 'will be confidential and will not be disclosed to third parties with the following exceptions:', \"When data are needed by the patient's personal physician or other medical personnel responsible for the\", \"patient's welfare. Prior written consent from the patient or legal guardian will first be obtained.\", 'For data inspection and verification by the IRB, or regulatory agency representatives.', 'Individual patient identity will not be divulged in any communication or publication.', 'In addition, this study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded', 'Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As such, this trial', 'will be registered at ClinicalTrials.gov, and results information from this trial will be submitted to ClinicalTrials.gov. In', 'addition, every attempt will be made to publish results in peer-reviewed journals. Data from this study may be', 'requested from other researchers after the completion of the primary endpoint by contacting the Data Coordinating', 'Center at UAB.', '11.1.12', 'CONFLICT OF INTEREST POLICY', 'The independence of this study from any actual or perceived influence is critical. Any actual or perceived conflicts of', 'interest of persons who have a role in the design, conduct, analysis, publication, or any aspect of this trial will be', 'disclosed and managed per the policies of the participating academic institutions. The respective academic institution', 'conflict of interest review boards have established policies and procedures for all study group members to disclose all', 'conflicts of interest and has mechanisms for the management of such conflicts.', '11.2 ADDITIONAL CONSIDERATIONS', '11.3 ABBREVIATIONS', 'The list below includes abbreviations utilized in this template. However, this list should be customized for each protocol', '(i.e., abbreviations not used should be removed and new abbreviations used should be added to this list).', 'Ab', 'Antibody', 'AE', 'Adverse Event', '41']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'CBC', 'Complete Blood Count', 'CCC', 'Clinical Coordinating Center', 'CFR', 'Code of Federal Regulation', 'CMP', 'Comprehensive Metabolic Panel', 'DCC', 'Data Coordination Center', 'DSMB', 'Data Safety Monitoring Board', 'eCRF', 'Electronic Case Report Form', 'eDES', 'Electronic Data Entry System', 'FAAN', 'Food Allergy and Anaphylaxis Network', 'FDA', 'Food and Drug Administration', 'G6PD', 'Glucose-6-Phosphate Dehydrogenase', 'GCP', 'Good Clinical Practice', 'GFR', 'Glomerular Filtration Rate', 'GIS', 'Gout Impact Scale', 'GOL', 'Golimumab', 'HEENT', 'Head, ears, eyes, nose, and throat exam', 'HIV', 'Human Immunodeficiency Virus', 'IBD', 'Inflammatory Bowel Disease', 'IC', 'Informed Consent', 'ICF', 'Informed Consent Form', 'Ig', 'Immunoglobulin', 'IMPDH', 'Inosine Monophosphate Dehydrogenase', 'IND', 'Investigational New Drug', 'IgG', 'Immunoglobulin G', 'IgM', 'Immunoglobulin M', 'IR', 'Infusion Reaction', 'IRB', 'Institutional Review Board', 'IV', 'Intravenous', 'mAbs', 'Monoclonal Antibodies', 'MMF', 'Mycophenolate Mofetil', 'MOOP', 'Manual of Operating Procedures', 'MPA', 'Moiety Mycophenolic Acid', 'MTX', 'Methotrexate', 'NIAMS', 'National Institute of Arthritis and Musculoskeletal and Skin', 'Diseases', 'NIH', 'National Institute of Health', 'PBO', 'Placebo', 'PEG', 'Polyethylene glycol', 'PI', 'Principal Investigator', 'PO', 'Per Orum', 'PRO', 'Patient Reported Outcome', 'PROMIS-29', 'Patient Reported Outcomes Measurement Information System', 'QOL', 'Quality of Life', 'RA', 'Rheumatoid Arthritis', 'RBC', 'Red Blood Cells', 'SAE', 'Serious Adverse Events', 'SAS', 'Statistical Analysis System', 'SOPs', 'Standard Operating Procedures', 'sUA', 'Serum urate', 'TB', 'Tuberculosis', '42']\n\n###\n\n", "completion": "END"}